[{"id":"5f6c2565-8588-4402-a34b-b3e63f38e1fa","acronym":"KANDLELIT-014","url":"https://clinicaltrials.gov/study/NCT07209111","created_at":"2025-10-11T01:29:13.435Z","updated_at":"2025-10-11T01:29:13.435Z","phase":"Phase 2","brief_title":"A Clinical Study of MK-1084 in People With Advanced Solid Tumors (MK-1084-014)","source_id_and_acronym":"NCT07209111 - KANDLELIT-014","lead_sponsor":"Merck Sharp \u0026 Dohme LLC","biomarkers":" KRAS","pipe":"","alterations":" ","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erbitux (cetuximab) • calderasib (MK-1084)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 150","initiation":"Initiation: 11/24/2025","start_date":" 11/24/2025","primary_txt":" Primary completion: 04/09/2032","primary_completion_date":" 04/09/2032","study_txt":" Completion: 04/09/2032","study_completion_date":" 04/09/2032","last_update_posted":"2025-10-06"},{"id":"b11c3dd5-a7d2-45b9-88bd-188586703589","acronym":"","url":"https://clinicaltrials.gov/study/NCT07190248","created_at":"2025-09-27T08:39:58.068Z","updated_at":"2025-09-27T08:39:58.068Z","phase":"Phase 3","brief_title":"A Clinical Study of MK-1084 and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)","source_id_and_acronym":"NCT07190248","lead_sponsor":"Merck Sharp \u0026 Dohme LLC","biomarkers":" PD-L1 • KRAS","pipe":"","alterations":" ","tags":["PD-L1 • KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • cisplatin • carboplatin • pemetrexed • calderasib (MK-1084)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 675","initiation":"Initiation: 10/27/2025","start_date":" 10/27/2025","primary_txt":" Primary completion: 12/07/2029","primary_completion_date":" 12/07/2029","study_txt":" Completion: 08/06/2032","study_completion_date":" 08/06/2032","last_update_posted":"2025-09-24"},{"id":"a81aca55-51bd-4c9d-98b4-44d67b97640e","acronym":"KANDLELIT-012","url":"https://clinicaltrials.gov/study/NCT06997497","created_at":"2025-06-07T14:50:31.299Z","updated_at":"2025-06-07T14:50:31.299Z","phase":"Phase 3","brief_title":"A Clinical Study of MK-1084 With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012)","source_id_and_acronym":"NCT06997497 - KANDLELIT-012","lead_sponsor":"Merck Sharp \u0026 Dohme LLC","biomarkers":" KRAS","pipe":"","alterations":" ","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Erbitux (cetuximab) • 5-fluorouracil • oxaliplatin • leucovorin calcium • calderasib (MK-1084) • levoleucovorin calcium"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 477","initiation":"Initiation: 07/17/2025","start_date":" 07/17/2025","primary_txt":" Primary completion: 08/27/2029","primary_completion_date":" 08/27/2029","study_txt":" Completion: 06/29/2031","study_completion_date":" 06/29/2031","last_update_posted":"2025-05-30"},{"id":"533b1900-f580-4f57-b6fc-c304162a280a","acronym":"MK-1084-004","url":"https://clinicaltrials.gov/study/NCT06345729","created_at":"2024-04-03T14:39:59.477Z","updated_at":"2025-02-25T12:30:27.021Z","phase":"Phase 3","brief_title":"A Study of MK-1084 Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant, Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004)","source_id_and_acronym":"NCT06345729 - MK-1084-004","lead_sponsor":"Merck Sharp \u0026 Dohme LLC","biomarkers":" KRAS","pipe":"","alterations":" ","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • calderasib (MK-1084)"],"overall_status":"Recruiting","enrollment":" Enrollment 600","initiation":"Initiation: 05/24/2024","start_date":" 05/24/2024","primary_txt":" Primary completion: 02/19/2029","primary_completion_date":" 02/19/2029","study_txt":" Completion: 02/18/2031","study_completion_date":" 02/18/2031","last_update_posted":"2025-02-24"},{"id":"482680df-b1a7-4f2f-8588-90fc2e8ec091","acronym":"MK-1084-001","url":"https://clinicaltrials.gov/study/NCT05067283","created_at":"2021-10-05T20:00:06.849Z","updated_at":"2025-02-25T15:19:17.925Z","phase":"Phase 1","brief_title":"A Study of MK-1084 in KRAS Mutant Advanced Solid Tumors (MK-1084-001)","source_id_and_acronym":"NCT05067283 - MK-1084-001","lead_sponsor":"Merck Sharp \u0026 Dohme LLC","biomarkers":" PD-L1 • KRAS","pipe":" | ","alterations":" KRAS mutation • KRAS G12C • KRAS G12","tags":["PD-L1 • KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • KRAS G12C • KRAS G12"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Erbitux (cetuximab) • carboplatin • 5-fluorouracil • pemetrexed • oxaliplatin • leucovorin calcium • calderasib (MK-1084)"],"overall_status":"Recruiting","enrollment":" Enrollment 830","initiation":"Initiation: 12/17/2021","start_date":" 12/17/2021","primary_txt":" Primary completion: 08/19/2027","primary_completion_date":" 08/19/2027","study_txt":" Completion: 08/19/2027","study_completion_date":" 08/19/2027","last_update_posted":"2025-02-11"}]